Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses

Akebia Therapeutics

07/05/2026 12:11

Overview

U.S. kidney disease drugmaker's Q1 revenue fell yr/yr on lower Auryxia sales

Adjusted EPS for Q1 met analyst expectations; net income and operating income missed

Company posted net loss due to lower revenue and higher R&D and SG&A expenses

Outlook

Akebia expects topline data from VOCAL trial in Q4 2026 and VOICE trial in early 2027

Company plans to initiate Phase 2 basket study for AKB-097 in rare kidney diseases in H2 2026

Akebia expects Auryxia revenues to decrease in 2026 due to expanding generic competition

Result Drivers

VAFSEO GROWTH - Higher Vafseo revenues driven by a 60% increase in patients and a 28% increase in prescribers compared to Q4 2025

AURYXIA DECLINE - Lower Auryxia revenues due to expanding generic competition

HIGHER EXPENSES - Increased R&D and SG&A costs from pipeline development and higher headcount

Company press release: ID:nGNX2JG3kZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Meet
-$0.03
-$0.03 (5 Analysts)
Q1 Net Income
Miss
-$9.05 mln
-$8.60 mln (5 Analysts)
Q1 Operating Income
Miss
-$4.70 mln
-$3.07 mln (5 Analysts)
Q1 Basic EPS
-$0.03
Q1 Operating Expenses
$45.95 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Akebia Therapeutics Inc is $4.00, about 170.3% above its May 6 closing price of $1.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)